You just read:

Pivotal study published in JAMA confirms potential of Novartis(1) vaccine Bexsero™ to help protect infants against devastating meningococcal serogroup B disease

News provided by

Novartis Pharmaceuticals Canada Inc.

Feb 09, 2012, 13:17 ET